Pfizer (PFE)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$28.45-1.25%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
QuarterlyIQ Insights · PFE
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -10.6% |
| Our one-year growth estimate | diamond | -4.8% |
Growth built into the price is above our model estimate.
The price assumes 5.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 10 industry peers · Company calendar date is not available
PFE — CFO transition
Dated 2026-06-18
Chief Financial Officer — Dave Denton: Dave Denton is leaving for a professional opportunity outside of the pharmaceutical industry.
Why it matters: Progress in research and development is key for future growth. It shows management cares about innovation.
Supportive ifAt least 10 important studies in cancer or obesity will start by year-end.
Worry ifFewer than 10 pivotal study starts announced by year-end.
Why it matters: CFO Dave Denton is leaving. This may affect Pfizer's money plans. Stable leadership is key.
Worry ifPfizer names a new CFO who carries out financial plans smoothly.
Less concerning ifFinancial results worsen or guidance is cut after the CFO change.
Why it matters: If revenue growth slows a lot, it may show less demand for Pfizer's products.
Worry ifQ3 revenue growth reported below 1% year over year.
Less concerning ifQ3 revenue growth reported above 1% year over year.
Why it matters: A new CFO can change the financial plan and affect investor trust.
Watch forThe new CFO uses a plan that keeps or improves financial guidance.
Also watch forThe new CFO's plan results in lower financial guidance or more uncertainty.
Why it matters: If sector growth slows, it could hurt Pfizer's performance. It signals broader industry challenges.
Worry ifSector revenue growth drops below its median for two consecutive months.
Less concerning ifSector revenue growth stays above its median for the same period.
Why it matters: Good news on key studies could mean more money from new products in the future.
Supportive ifAnnouncement of at least 5 new pivotal study starts in the next quarter.
Worry ifNo new pivotal study starts announced in the next quarter.
Why it matters: Pfizer thinks Seagen will bring in over $10 billion by 2030. This could help Pfizer grow in cancer treatment.
Supportive ifSeagen made over $2.2 billion in 2023. This shows strong growth.
Worry ifSeagen's revenue is below $2 billion in 2023. This shows weaker integration.
Why it matters: Getting these savings would show good cost management and help profits.
Supportive ifAnnouncement of achieving $2.5 billion in cost savings by end of 2026.
Worry ifNo announcement of cost savings progress by end of 2026.
Why it matters: Starting ~20 pivotal studies is key for future growth. Progress here signals strong R&D momentum.
Supportive ifAnnouncement of at least 10 pivotal studies initiated by the end of Q3 2026.
Worry ifFewer than 10 pivotal studies initiated by the end of Q3 2026.
Why it matters: Pfizer's revenue guidance of $59.5 to $62.5 billion is key for investor trust. Steady guidance helps keep stability.
Supportive ifPfizer reaffirms full-year 2026 guidance during the next earnings call on August 4, 2026.
Worry ifPfizer lowers its full-year 2026 guidance below $59.5 billion.
Why it matters: Progress in research means there is potential for future growth and new products.
Supportive ifPfizer will start about 20 important studies in 2026 as planned.
Worry ifPfizer announces delays or fewer than 20 pivotal study starts in 2026.
Why it matters: Strong growth in this area shows Pfizer can balance COVID-19 product losses.
Supportive ifRevenue from new and acquired products grows over 15% each year.
Worry ifRevenue from new and acquired products drops below 10% each year.
Why it matters: Saving $5.7 billion is important for staying profitable. This shows good management.
Supportive ifManagement reports achieving at least $2 billion in net savings by the end of 2026.
Worry ifNet savings reported below $2 billion by the end of 2026.
Why it matters: A smooth change may keep trust in financial plans. Problems could hurt investor feelings.
Watch forCecile Guegan confirms full-year 2026 guidance stays the same.
Also watch forCecile Guegan cuts the full-year guidance for 2026.
Why it matters: Reaffirming EPS guidance signals strong earnings potential. It can boost investor confidence.
Supportive ifManagement says the full-year 2026 EPS guidance will not change in the next call.
Worry ifManagement lowers or withdraws the full-year 2026 EPS guidance.
Why it matters: Reaffirming guidance shows Pfizer is confident in meeting financial goals. It shows strength in operations.
Supportive ifPfizer reaffirms full-year 2026 revenue guidance between $60.5 and $62.5 billion.
Worry ifPfizer lowers its revenue guidance below $60.5 billion.
Why it matters: Good trial results could improve Pfizer's drug pipeline. This can help growth in important areas.
Supportive ifGood Phase 3 results for cancer or obesity products were announced.
Worry ifBad results from key trials in cancer or obesity.
Why it matters: Saving costs is key for better margins and making more money.
Supportive ifPfizer announces progress toward the $5.7 billion net cost savings target by 2027.
Worry ifPfizer reports delays or setbacks in achieving cost savings targets.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$95 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $227 loss on $10,000 · 2.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,709 loss on $10,000 · 17.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.